Clinical trial · no report yet · Phase 3
OrigAMI-2
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- NCT06662786 ↗
- Recruiting
- Janssen Research & Development, LLC
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| Podcasts | 3 | |
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Colorectal Neoplasms
- Interventions
- Amivantamab; Cetuximab; 5-fluorouracil; Leucovorin calcium/Levoleucovorin; Oxaliplatin; Irinotecan Hydrochloride
- Arms
- Arm A: Amivantamab in Combination With Chemotherapy · Experimental
- Arm B: Cetuximab in Combination With Chemotherapy · Active comparator
- Enrollment
- 1,000 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Oct 18, 2024
- Primary completion
- Dec 15, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06662786 · updated Sep 25, 2026